Bristol/Gilead HIV Combo Therapy Will Go To FDA By Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb and Gilead plan to submit an NDA in the second quarter for a fixed-dose combination of Bristol’s Sustiva (efavirenz) and Gilead’s Truvada (emtricitabine/tenofovir disoproxil).
You may also be interested in...
Bristol/Gilead submit Truvada/Sustiva combo
Bristol-Myers Squibb and Gilead's fixed-dosed combination of Bristol's Sustiva (efavirenz) and Gilead's Truvada (emtricitabine/tenofovir) could be on the market by the first quarter of 2007. Bristol completed the submission of the triple-combo antiretroviral in late April, putting an estimated standard review action date in February 2007. If approved, the combination "would be the first and only product that contains a complete highly active antiretroviral therapy [HIV] regimen in a single once-daily tablet," the firms note. While the sponsors initially ran into bioequivalence issues, they announced in January that they had obtained data supporting bioequivalence (1Pharmaceutical Approvals Monthly January 2006, p. 26)...
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
Bristol/Gilead joint venture targets 2005 filing for fixed-dose HIV combo. A new brand name for the fixed-dose combination of Bristol’s Sustiva and Gilead’s Truvada is expected. Firms will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products”
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011